NATCO launches anticoagulant drug Rivaroxaban in India
Hyderabad: Natco Pharma Limited has recently announced the launch of Rivaroxaban molecule, under brand RPIGAT.
Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots.
Rivaroxaban is currently sold by Bayer under brand name of Xarelto, in the Indian market.
"After successful previous launches of DABIGAT (Dabigatran) and APIGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line with our Company's mission of affordable medicines accessible to all," the release stated.
NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of INR 14.0 per tablet.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.